Clinical Trials Regulation’s Impact on Localization

In our 8th life sciences localization blog series post, we’ll be discussing the impact of the Clinical Trials Regulation (EU) No 536/2014 on localization. The CTR marks a significant milestone in the harmonization of clinical trial procedures across the European Union. Its primary aim is to ensure a more streamlined and efficient framework for conducting clinical trials, with an enhanced emphasis on safety, transparency, and data reliability.  

Clinical Trials Regulation’s Impact on Localization Read More »

Adapting to MDR Localization Challenges 

The implementation of the Medical Device Regulation (MDR) EU 2017/745 marks a significant shift in the regulatory landscape for medical devices within the European Union. This comprehensive framework not only aims to ensure a higher level of patient safety but also to facilitate the free and unhindered movement of medical devices within the EU market. The transition to MDR’s new regulations, especially during localization, presents a series of volume and timing challenges that require careful navigation and strategic adaptation. 

Adapting to MDR Localization Challenges  Read More »

Global Life Sciences Success Through Precise Localization

In the dynamic realm of life sciences, precise and culturally attuned translations are indispensable for global success. The life sciences sector demands unparalleled accuracy in translation, where major errors in product labels, patient consent forms, or research documents can compromise patient safety and invite legal challenges. High translation quality transcends regulatory compliance; it is vital

Global Life Sciences Success Through Precise Localization Read More »

Unique Challenges in Life Sciences Localization 

In the rapidly evolving landscape of global healthcare, life sciences companies are navigating through a sea of regulatory changes that create significant challenges in their localization strategies. The introduction of new regulations has ushered in a new era of compliance, clinical evaluation, and post-market surveillance. These requirements, captured in the Medical Device Regulation (MDR, EU 2017/745), the In Vitro Diagnostic Regulation (IVDR, EU 2017/746), and the Clinical Trial Regulation (EU 536/2014) set the stage for a series of unique challenges in life sciences localization efforts. 

Unique Challenges in Life Sciences Localization  Read More »

Establishing a unified culture of quality and transparency

Creating a unified culture of quality and transparency between life sciences companies and their localization service providers (LSPs) is not just beneficial—it’s imperative. The stakes in the life sciences industry are exceptionally high, with the wellbeing of patients and the integrity of global health initiatives on the line. Newer regulations applicable to medical devices, pharmaceutical products, and clinical trials bring with them increased volume and decreased localization turnaround times.  
Achieving a seamless partnership that emphasizes quality and transparency can significantly impact the success of bringing medical devices, pharmaceuticals, and biotechnology products to global markets. This blog post explores the importance of establishing such a culture and offers strategies for both life sciences companies and LSPs to foster this critical collaboration.

Establishing a unified culture of quality and transparency Read More »

Translation Quality: Back to the Future

Twenty years ago, measured translation quality was a budding topic in linguistic services. Now, as we navigate through the era of Large Language Models (LLMs), it’s time to forecast the future of measured translation quality. While working at ForeignExchange Translations, I co-authored a book on measured translation quality with Jason Arnsparger. The core theme centered

Translation Quality: Back to the Future Read More »